Neuraxis (NRXS) Change in Account Payables (2022 - 2025)
Neuraxis (NRXS) posted Change in Account Payables of -$747034.0 for Q4 2025, down 277.07% sequentially from $421881.0 in Q3 2025, and down 104.58% YoY from $16.3 million in Q4 2024.
Neuraxis (NRXS) Change in Account Payables (2022 - 2025) Analysis & Trends
Neuraxis has reported Change in Account Payables for 4 years, with the latest figure at -$747034.0 in Q4 2025.
- Quarterly Change in Account Payables fell 104.58% year-over-year to -$747034.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$457583.0 (up 24.65% YoY) and the FY2025 annual result came in at -$457583.0, up 24.65% from the prior year.
- Change in Account Payables fell to -$747034.0 in Q4 2025 per NRXS's latest filing, from $421881.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $748674.0 in Q4 2022 and troughed at -$1.9 million in Q3 2023.
- A 4-year average of -$16133.3 and a median of -$14555.0 in 2024 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2025: Change in Account Payables sank 491.35% in 2023, then jumped 370.07% in 2025.
- Over 4 years, Change in Account Payables stood at $748674.0 in 2022, then decreased by 14.84% to $637570.0 in 2023, then tumbled by 157.27% to -$365161.0 in 2024, then slumped by 104.58% to -$747034.0 in 2025.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$747034.0, $421881.0, and -$70499.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -747,034.00 |
| Dec 31, 2025 | -747,034.00 |
| Sep 30, 2025 | 421,881.00 |
| Sep 30, 2025 | 421,881.00 |
| Jun 30, 2025 | -70,499.00 |
| Jun 30, 2025 | -70,499.00 |
| Mar 31, 2025 | -61,931.00 |
| Mar 31, 2025 | -61,931.00 |
| Dec 31, 2024 | -365,161.00 |
| Dec 31, 2024 | -365,161.00 |
| Sep 30, 2024 | -156,210.00 |
| Sep 30, 2024 | -156,210.00 |
| Jun 30, 2024 | -118,723.00 |
| Jun 30, 2024 | -118,723.00 |
| Mar 31, 2024 | 32,821.00 |
| Mar 31, 2024 | 32,821.00 |
| Dec 31, 2023 | 637,570.00 |
| Dec 31, 2023 | 637,570.00 |
| Sep 30, 2023 | -1.87 Mn |
| Sep 30, 2023 | -1.87 Mn |